Baird raised the firm’s price target on Bright Minds (DRUG) to $142 from $82 and keeps an Outperform rating on the shares. The firm updated its model following the release of data from its BMB-101 trial data which showed an absence of seizures.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRUG:
- Bright Minds price target raised to $147 from $72 at BTIG
- Bright Minds Biosciences Launches US$100 Million Public Offering to Fund CNS Drug Pipeline
- Bright Minds Biosciences: Encouraging BMB-101 Efficacy, Pipeline Expansion, and Valuation Upside Support Maintained Buy Rating
- Bright Minds Biosciences Unveils Strong Phase 2 Data for BMB-101 in Drug-Resistant Seizure Disorders
- Bright Minds announces $100M common shares offering